MVD-affected dogs which really needed the drug could not be treated with it because no one had an inventory of it
But how we handle this phase will shape everything that comes next.
Guivarch PH, Castaigne JP, Gagnon L, Peslherbe L, Dreyfus JH, Drucher DJ
A., Othman, N
An indirect comparison of data by Novo Nordisk from the STEP 1 trial and the SCALE trial of daily GLP-1 agonist liraglutide suggested 5.81% more weight loss with semaglutide than liraglutide at 68 weeks, and this was backed up by data from the STEP 8 trial, which directly compared the two treatments[1,3,4]
Integrating exercise, adequate protein intake, and potentially adjunctive pharmacotherapies is essential to mitigate this risk